3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer -

UK cancer patients “wait too long” for treatment

CancerJan 12, 06

Many British patients suffering from cancer are waiting too long before being seen by a specialist, although referral times have improved over the last five years, a House of Commons committee said on Thursday.

Around 40 percent of people ultimately diagnosed with cancer were not referred urgently and were not seen by a specialist within two weeks of referral in 2004, the Public Accounts Committee said in a report.

“Cancer patients are being looked after better than they were five years ago and generally well,” said the committee’s chairman Edward Leigh.

“But the experience of cancer sufferers is not as good as it could be. Too many are waiting too long to see a specialist following referral by a GP.”

More than one quarter of bowel cancer patients had to wait more than one month in 2004 to see a specialist after being referred by their family doctor, during which time around 30 percent said their condition had deteriorated.

In the same year just 32 percent of prostate cancer patients were seen within two weeks, compared to 70 percent of patients with breast cancer, an inequality Leigh said was “unacceptable.”

The government has since committed itself to “demonstrably large improvements” in prostate cancer care, the committee said.

Health Minister Rosie Winterton said cancer death rates had fallen by 14 percent since 1996 but accepted more could be done to help cancer sufferers.

“Patients are seeing the benefits of more staff, more modern equipment such as scanners to detect cancer, shorter waiting times to see a specialist and increased access to the latest drugs,” she said.

“The report also recognises that there is more work to be done. We acknowledge this and have put actions in place to maintain the momentum of improvement.”



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site